Stopping versus continuing renin–angiotensin–system inhibitors after acute kidney injury and adverse clinical outcomes: an observational study from routine care data

BACKGROUND: The risk–benefit ratio of continuing with renin–angiotensin system inhibitors (RASi) after an episode of acute kidney injury (AKI) is unclear. While stopping RASi may prevent recurrent AKI or hyperkalaemia, it may deprive patients of the cardiovascular benefits of using RASi. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Janse, Roemer J, Fu, Edouard L, Clase, Catherine M, Tomlinson, Laurie, Lindholm, Bengt, van Diepen, Merel, Dekker, Friedo W, Carrero, Juan-Jesus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155253/
https://www.ncbi.nlm.nih.gov/pubmed/35664269
http://dx.doi.org/10.1093/ckj/sfac003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155253/
https://www.ncbi.nlm.nih.gov/pubmed/35664269
http://dx.doi.org/10.1093/ckj/sfac003

Ejemplares similares